An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians

Pharmacogenetics

Volumn 8, Issue 2, 1998, Pages 129-135

  Ibeanu, Gordon C ^a   Blaisdell, Joyce ^a   Ghanayem, Burhan I ^a   Beyeler, Christine ^b,d   Benhamou, Simone ^c   Bouchardy, Christine ^b,d   Wilkinson, Grant R ^e   Dayer, Pierre ^f   Daly, Ann K ^g   Goldstein, Joyce A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c INSERM   (France)

^d GENEVA CANCER REGISTRY   (Switzerland)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CYP2C19; Mephenytoin; Polymorphisms

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 ISOENZYME; MEPHENYTOIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CAUCASIAN; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; ETHNIC GROUP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MUTATION; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

EID: 15644372745     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199804000-00006     Document Type: Article

References (41)

1. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR. Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mepbenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 1994; 4:27-38.
2. Andersson T, Regardh C-G, Lou Y-C, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2:25-31.
3. Balian JD, Sukhova N, Harris JW, Hewett J, Pickel L, Goldstein JA et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995; 57:662-669.
4. Barnes HJ, Arlotto MP, Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylcase in Escherichia coli. Proc Natl Acad Sci USA (USA) 88:5597-5601.
5. Baumann P, Jonzier-Perez M, Kerb L, Küpfer A, Tingueley D, Schöpf J. Amitriptyline pharmacokinetics and clinical response. II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1:102-112.
6. Benhamou S, Bouchardy C, Dayer P. Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics, 1997; 7:157-159.
7. Bertilsson L, Henthorn TK, Sanz H, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin but not debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 1989; 45:348-355.
8. Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease severity. J Rheumatol 1994; 21:1054-1039.
9. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
10. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5:312-317.
11. Curnow KM, Slutsker L, Vitek J, Cole T, Spieser PW, New MI et al. Mutations in the CYP11B1 gene causing cogenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci USA 1993; 90:4552-1556.
12. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
13. Deng WP, Nickoloff JA. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal Biochem 1992; 200:81-88.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994a; 269:15419-15422.
15. de Morals SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b; 46:594-958.
16. de Morais SMF, Goldstein JA, Xie HG, Huang S-L, Lu YQ, Xia H et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharm Ther 1995; 58:404-412.
17. Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G et al. A novel defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of mephenytoin. J Pharmacol Exp Ther 1998; 284:356-361.
18. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL et al. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry 1994; 33:1743-1752.
19. Goldstein JA, Blaisdell J. Genetic tests which identify the principle defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In: Johnson EF, Waterman MR editors. Methods in enzymology, Vol 272, Cytochrome P450. Part B. San Diego: Academic Press: 1996. pp. 210-217.
20. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various oriental, Caucasian, Saudi Arabian and American Black populations. Pharmacogenetics 1997; 7:59-64.
21. Hahn GJ, Meeker WQ. Statistical intervals: a guide for practitioners. Chichester: John Wiley & Sons, Inc; 1991. pp. 104-105.
22. Ibeanu GC, Ghanayem BI, Linko P, Li-L, Pederson LG, Goldstein JA. Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole activity. J Biol Chem 1996; 271:12496-12501.
23. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson E. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proc Natl Acad Sci USA 1993; 90:11673-11677.
24. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26:753-759.
25. Kupfer A, Branch RA. Stereo selective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985; 38:414-418.
26. Omura T, Sato, R. The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 1964; 239:2370-2378.
27. Nielsen K, Brøsen K, Hansen J, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine/debrisoquine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55:518-527.
28. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B et al. A universal approach to the expression of human and rabbit cytochrome P450 of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 1995; 323:87-96.
29. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 1991; 30:3247-3255.
30. Sarich TC, Kalhorn TF, Magee S, Blaisdell J, Al Sayeh F, Adams SP et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharm Ther 1997; 62:21-28.
31. Sindrup SH, Brøsen K, Hansen MGJ, Aaes-Jorgensen T, Overo KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993; 13:11-17.
32. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidative polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49:18-23.
33. Tartof KD, Hobbs CA. Improved media for growing plasmid and cosmid clones. Bethesda Res Lab Focus 1987; 9:19.
34. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin Pharmacol Ther 1989; 45:72-79.
35. Ward SA, Helsby NA, Skejlbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31:689-692.
36. Wedlund PJ, Sweetman BJ, McAllister CB, Branch RA, Wilkinson GR. Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. J Chromatogr B Biomed Appl 1984; 307:121-127.
37. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA. Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metab Dispos 1987; 15:277-279.
38. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43:53-76.
39. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306:240-245.
40. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH et al. Differences in the incidence of the CVP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exper Ther 1997; 281:604-609.
41. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation of the use of urinary S/R mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1992; 31:350-352.